GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Net Cash per Share

Mural Oncology (Mural Oncology) Net Cash per Share : $12.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Mural Oncology's Net Cash per Share for the quarter that ended in Mar. 2024 was $12.00.

The historical rank and industry rank for Mural Oncology's Net Cash per Share or its related term are showing as below:

MURA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.27   Med: 0.42   Max: 0.42
Current: 0.27

During the past 3 years, the highest Price-to-Net-Cash Ratio of Mural Oncology was 0.42. The lowest was 0.27. And the median was 0.42.

MURA's Price-to-Net-Cash is ranked better than
98.96% of 862 companies
in the Biotechnology industry
Industry Median: 3.87 vs MURA: 0.27

Mural Oncology Net Cash per Share Historical Data

The historical data trend for Mural Oncology's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Net Cash per Share Chart

Mural Oncology Annual Data
Trend Dec21 Dec22 Dec23
Net Cash per Share
-3.18 -3.32 13.96

Mural Oncology Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only - 15.39 -2.22 13.96 12.00

Competitive Comparison of Mural Oncology's Net Cash per Share

For the Biotechnology subindustry, Mural Oncology's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mural Oncology's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Price-to-Net-Cash falls into.



Mural Oncology Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Mural Oncology's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(270.852-37.928-0)/16.6897
=13.96

Mural Oncology's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(231.674-28.577-0)/16.9226
=12.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mural Oncology  (NAS:MURA) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Mural Oncology Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Mural Oncology (Mural Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin, IRL, D02 T380
Website
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.

Mural Oncology (Mural Oncology) Headlines